Pathos AI partners with Bristol Myers Squibb and Tempus AI to accelerate medical research

Bristol Myers Squibb (BMY) shared Phase 1 data for zolacabtagene autoleucel (zola-cel) in MS patients, showing promising results. Separately, BMY expanded its AI collaboration with Tempus (TEM) through 2031. BMY stock is down 2.30%, TEM up 1.54%.

Bristol Myers Squibb (BMY) reported interim Phase 1 Breakfree-2 study results for its CAR T-cell therapy zolacabtagene autoleucel in 66 multiple sclerosis patients. 92% of progressive MS patients showed stable or improved disability. Safety issues included cytokine release syndrome in 42.4% of patients. BMY stock is down 2.26% at $61.56.

SystImmune and Bristol Myers Squibb reported positive Phase 3 trial results for iza-bren in HR+/HER2- breast cancer. The treatment reduced disease progression or death risk by 59% vs. chemotherapy, with a 40.5% response rate. Safety profile was manageable, with low discontinuation rates. Sichuan Biokin Pharmaceutical conducted the study.

Bristol Myers Squibb (BMY) presented interim Phase 1 study results for zolacabtagene autoleucel, a CAR T cell therapy for multiple sclerosis, at the MSToronto 2026 meeting. The study enrolled 66 patients, with safety and efficacy as primary and secondary endpoints. Key findings included cytokine release syndrome in 42.4% of patients, one death from septic pneumonia, and positive efficacy signals in both relapsing and progressive MS patients.

Tempus AI and Bristol Myers Squibb extended their partnership with a multi-year deal for oncological data and AI platform access. The agreement, running through 2031, includes $137.5 million from Bristol Myers and $55 million from Pathos AI for patient records. Pathos AI is also collaborating with both companies on neurological conditions.

Bristol Myers Squibb (BMY) presented interim Phase 1 Breakfree-2 study results for zolacabtagene autoleucel (zola-cel) in patients with highly active relapsing and progressive multiple sclerosis (MS). The study showed promising safety and efficacy, with 42.4% of patients experiencing cytokine release syndrome (CRS) and 7.6% immune effector cell-associated neurotoxicity syndrome (ICANS). All patients treated at dose level 2 remained off disease-modifying therapies (DMTs).